Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT03634228
Title Milademetan Tosylate and Low-Dose Cytarabine With or Without Venetoclax in Treating Participants With Recurrent or Refractory Acute Myeloid Leukemia
Recruitment Completed
Gender both
Phase Phase Ib/II
Variant Requirements Yes
Sponsors M.D. Anderson Cancer Center

acute myeloid leukemia


Cytarabine + Milademetan Tosylate

Cytarabine + Milademetan Tosylate + Venetoclax

Age Groups: senior | adult
Covered Countries USA

Additional content available in CKB BOOST